Inversago Pharma, a Montreal, Canada-based clinical stage biotech company, raised CA$95M in Series C funding.
The round was led by New Enterprise Associates, with participation from Forbion’s Growth, Amgen Ventures, Forbion Ventures, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations.
The company intends to use the funds to move Its program, INV-202, into a Phase 2 clinical trial in Diabetic Kidney Disease in Q4 2022.
Led by CEO François Ravenelle, Inversago Pharma is a biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on, peripherally-acting CB1 inverse agonists. The company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease, including Diabetic Nephropathy, Type 1 and Type 2 Diabetes, Non-Alcoholic Steatohepatitis, complications of obesity and hypertriglyceridemia, as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease, including Idiopathic Pulmonary Fibrosis and other conditions.
FinSMEs
17/10/2022